Biomarker driven umbrella trial of crenolanib in combination with ivosidenib, enasidenib, venetoclax, vyxeos and/or salvage chemotherapy in FLT3 mutant AML Meeting Abstract
| Authors: | Daver, N.; Goldberg, A. D.; DiNardo, C. D.; Kadia, T. M.; Wang, E. S.; Stone, R. M.; Zhang, H.; Messahel, B. |
| Abstract Title: | Biomarker driven umbrella trial of crenolanib in combination with ivosidenib, enasidenib, venetoclax, vyxeos and/or salvage chemotherapy in FLT3 mutant AML |
| Meeting Title: | 62nd Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 136 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2020 Dec 5-8 |
| Meeting Location: | Virtual |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2020-11-05 |
| Language: | English |
| ACCESSION: | WOS:000607205604001 |
| DOI: | 10.1182/blood-2020-140378 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 16 -- Source: Wos |
